Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint
- PMID: 31112312
- DOI: 10.1111/nan.12568
Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint
Abstract
Neuroendocrine tumours of the adenohypophysis have traditionally been designated as pituitary adenomas to underline their usually indolent growth and lack of metastatic potential. However, they may demonstrate a huge spectrum of growth patterns and endocrine disturbances, some of them significantly affecting health and quality of life. To predict tumour growth, risk of postoperative recurrence and response to medical therapy in patients with pituitary neuroendocrine tumours is challenging. A thorough histopathological and immunohistochemical diagnostic work-up is an obligatory part of a multidisciplinary effort to precisely define the tumour type and assess prognostic and predictive factors on an individual basis. In this review, we have summarized the current status in the pathology in pituitary neuroendocrine tumours based on the selection of references from the PubMed database. We have presented possible diagnostic approaches according to the current pituitary cell lineage-based classification. The importance of recognizing histological subtypes with potentially aggressive behaviour and identification of prognostic and predictive tissue biomarkers have been highlighted. Controversies related to particular subtypes of pituitary tumours and a still limited prognostic impact of the current classification indicate the need for further refinement. Multidisciplinary approach including clinical, pathological and molecular genetic characterization will be essential for improved personalized therapy and the search for novel therapeutic targets in patients with pituitary neuroendocrine tumours.
Keywords: diagnostic approach; pituitary adenoma; pituitary neuroendocrine tumour; predictive markers; prognostic markers; transcription factors.
© 2019 British Neuropathological Society.
Similar articles
-
[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].Probl Endokrinol (Mosk). 2023 Nov 14;70(3):31-45. doi: 10.14341/probl13376. Probl Endokrinol (Mosk). 2023. PMID: 39069771 Free PMC article. Review. Russian.
-
How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies.Front Endocrinol (Lausanne). 2021 Mar 17;12:604644. doi: 10.3389/fendo.2021.604644. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815274 Free PMC article. Review.
-
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients.Minerva Endocrinol (Torino). 2024 Sep;49(3):269-282. doi: 10.23736/S2724-6507.24.04126-5. Epub 2024 Jul 4. Minerva Endocrinol (Torino). 2024. PMID: 38963295 Review.
-
Newer Concepts in the Classification of Pituitary Adenomas.Neurol India. 2020 May-Jun;68(Supplement):S7-S12. doi: 10.4103/0028-3886.287667. Neurol India. 2020. PMID: 32611886 Review.
-
Histopathological classification of non-functioning pituitary neuroendocrine tumors.Pituitary. 2018 Apr;21(2):119-129. doi: 10.1007/s11102-017-0855-1. Pituitary. 2018. PMID: 29275530 Free PMC article. Review.
Cited by
-
Overview of the 2022 WHO Classification of Pituitary Tumors.Endocr Pathol. 2022 Mar;33(1):6-26. doi: 10.1007/s12022-022-09703-7. Epub 2022 Mar 15. Endocr Pathol. 2022. PMID: 35291028 Review.
-
Architects of Pituitary Tumour Growth.Front Endocrinol (Lausanne). 2022 Jun 28;13:924942. doi: 10.3389/fendo.2022.924942. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35837315 Free PMC article. Review.
-
The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.Brain Pathol. 2025 Jan;35(1):e13302. doi: 10.1111/bpa.13302. Epub 2024 Sep 1. Brain Pathol. 2025. PMID: 39218431 Free PMC article. Review.
-
Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.J Clin Endocrinol Metab. 2023 Jun 16;108(7):1585-1601. doi: 10.1210/clinem/dgad098. J Clin Endocrinol Metab. 2023. PMID: 36856733 Free PMC article.
-
Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway.Neuropathol Appl Neurobiol. 2021 Apr;47(3):415-427. doi: 10.1111/nan.12675. Epub 2020 Dec 20. Neuropathol Appl Neurobiol. 2021. PMID: 33128255 Free PMC article.
References
-
- Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017; 24: C5-8
-
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization Classification of Tumours of the Central Nervous System. Revised, 4th edn. Lyon: IARC Press, 2016
-
- Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18: e315-29
-
- Lloyd RV, Osamura RY, Kloppel G, Rosai J. World Health Organization classification of tumours of endocrine organs, 4th edn. Lyon: IARC Press, 2017
-
- Rindi G, Klimstra D, Abedi-Ardekani B, Asa S, Bosman F, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31: 1770-86
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical